[go: up one dir, main page]

WO2002024212A1 - Cholesterol in blood-lowering composition and its complex, and method for preparing them - Google Patents

Cholesterol in blood-lowering composition and its complex, and method for preparing them Download PDF

Info

Publication number
WO2002024212A1
WO2002024212A1 PCT/KR2000/001034 KR0001034W WO0224212A1 WO 2002024212 A1 WO2002024212 A1 WO 2002024212A1 KR 0001034 W KR0001034 W KR 0001034W WO 0224212 A1 WO0224212 A1 WO 0224212A1
Authority
WO
WIPO (PCT)
Prior art keywords
cholesterol
blood
reducing
phyto
sterol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/KR2000/001034
Other languages
French (fr)
Korean (ko)
Inventor
Sang Nam Lee
Yang Hun Song
Soo Kil Kim
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
ULTIMATE LIFE TECHNOLOGY Co Ltd
Original Assignee
ULTIMATE LIFE TECHNOLOGY Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ULTIMATE LIFE TECHNOLOGY Co Ltd filed Critical ULTIMATE LIFE TECHNOLOGY Co Ltd
Priority to PCT/KR2000/001034 priority Critical patent/WO2002024212A1/en
Priority to AU2000274550A priority patent/AU2000274550A1/en
Publication of WO2002024212A1 publication Critical patent/WO2002024212A1/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/31Brassicaceae or Cruciferae (Mustard family), e.g. broccoli, cabbage or kohlrabi

Definitions

  • the present invention relates to the composition and the complex for reducing the cholesterol in the blood, particularly LDL cholesterol, and for curing the cholesteremia or some of heart diseases, as well as to the method for manufacturing those compositions and complex substances, wherein complexes or mixed compositions consisting of phyto-sterols, naturally occurring plant sterols and tannins, as the main components, are used as pharmaceutical preparations, medicinal injections, food additives or the like.
  • the cholesterol is an essential substance in human body, which plays a role in forming cell membrane, steroid hormones or the like.
  • the in-blood concentration of cholesterol, particularly LDL cholesterol or the lipid is maintained at excessively high level, however, there is a high possibility of heart diseases or arterial sclerosis, which can lead to death or disability.
  • the plant sterols are effective in controlling the choiesterols in the blood substantially without causing harmful effects (Reference: J. Nutr., 107, 2011 (1977)).
  • the beta-cytosterol which is advantageously acquired from bean or rice in easy ways and which turns similar to the cholesterol in structure when the ethyl group at the 24-th carbon is removed, has been confirmed to interfere with the cholesterol absorption in the human body through a competitive reaction (Reference: Atherosclerosis, 28, 325, (1977)).
  • Naturally occurring plant sterols have the same skeleton in the structure, only slightly differing in side chains.
  • the plant sterols taken-in together with foodstuffs are mostly either beta-cytosterols or campysterols, some of which are absorbed in the intestine and then discharged outside the body, so that even an over- intake causes no side effect on the human body due to only a minor part of it remaining in the body.
  • their analogous products i.e. stanol as hydrogenated compounds and their fatty acid ester compounds were also developed as the products for reducing in-blood choiesterols (Reference: J. Lipid Res., 20, 646, (1979); J.
  • the complex for reducing the in-blood cholesterol according to the present invention comprises, as the principal components, natural plant sterol ("phyto-sterol”) and tannin at the weight ratio of 10: 1 to 1:10.
  • phyto-sterol natural plant sterol
  • tannin tannin
  • the present inventors have confirmed that the phyto-sterol/tannin complexes manufactured by mixing naturally occurring plant sterols as harmless safe substances, and tannins have an unexpected synergic effect in reducing the in-blood choiesterols and so completed the present invention based on that finding.
  • phytosterols beta-cytosterols, campy-sterols, stigma sterols, fuco-sterols, Brassica sterols may be mentioned.
  • One of those sterols or a mixture of two or more may be used as the principal component for the products according to the invention.
  • the tannins as described above are generally included in the stems, leaves, roots of plants or the like, and also in the fruits and vegetables including unripe ones, as well as in the seeds of plants.
  • the tannin compounds have various physiological activities, which include, for example, the action of improving the blood circulation, anti-oxidation and other various physiological activations.
  • the tannins may be classified as (1) catechins and their derivatives, (2) leucoanthocyanins,
  • chlorogenic acids which all belong to polyphenolic acids with phenol group(s).
  • the tannin compounds as described above can be used as a single compound or in the form of mixture of two or more compounds.
  • catechins which have the carbon skeletons of C 6 -C 3 -C 6 , i.e. a structural characteristic common to the flavonoids, anthocyanins and the like. Under these tannins, catechins
  • Typical leucoanthocyanins may include leucoanthocyanidin, luteolinidin and the like.
  • the anthocyanidins have the basic structure of 3,5,7-trihydroxy flavylium chlorides.
  • the anthocyanidin includes pelargonidin, cyaniding and delphinidin as the representative examples and further includes hirsutidin (7-o-methylmalvidin), aurantinidin (8-hydroxy pelargonidin), apigeninidin (3-deoxy pelargonidin), petunidin
  • the representative examples of the above-described polyphenolic acids include chlorogenic acids, caffeine acid, phenyl caffeate, cinnamic acid, gallic acid and the tannic acid that is now known as a complex mixture of various compounds.
  • the tannins have a variety of distributions and contents and they can be relatively easily extracted to give certain desired tannin.
  • the content ratio between phyto-sterol and tannin as the principal components of the complex according to the invention lies between 10:1 and 1:10 and more preferably between 4:6 and 6:4, each ratio being by weight, as mentioned earlier.
  • the present invention relates to a mixed composition comprising, as the principal components, phyto-sterol and tannin at the weight ratio of 10: 1 to 1 : 10 for reducing the cholesterol in the blood.
  • the complex of phyto-sterol and tannin which is obtained by dissolving the phyto-sterol and tannin together in a solvent and then heat-treating the dissolved mixture at a defined condition further increases the synergic effect of mixing the two ingredients.
  • the present invention relates to a method for manufacturing a complex of phyto-sterol/tannin as well.
  • the method for manufacturing the complex for reducing the in-blood cholesterol according to the present invention comprises dissolving the dried phyto- sterol and tannin in a solvent under an acidic condition, subjecting the dissolved mixture to reaction at a temperature from 20 to 100°C, removing the remaining solvent from the product and finally subjecting the crude product to drying.
  • the manufacturing method comprises the steps of:
  • the temperature in the above steps (C) and (D) is about 70°C and the heating period is 5 to 30 minutes.
  • the solvent used in the step (B) the water, ethanol or a mixture of water and ethanol may be appropriate.
  • the weak solution for the step (D) preferably an edible acidic solution and most preferably vinegar from fruit may be used.
  • the complex and mixed composition according to the invention may be prepared into pharmaceutical formulations, medicinal injections, food additives or the like for reducing the cholesterol level in the blood.
  • a pharmaceutical formulation may be prepared by adding some vehicle to the above-described complex as the active ingredient.
  • a medicinal injection may be prepared by dissolving the above complex as the active ingredient in distilled water or saline solution as the solvent.
  • powder of the complex is simply added to the raw material of foodstuffs and finished foodstuffs.
  • the present invention relates to the agents for reducing cholesterol, injections for reducing cholesterol, food additives for reducing cholesterol, each containing the above-described complexes or mixed compositions as the active ingredients, and various foodstuffs containing the above complexes.
  • the method for preparing the above agents, injections and foodstuffs is the same as the method for preparing ordinary medicinal agents or injections based on the medicinal active components, and therefore is no more described.
  • addition can be made in a variety of ways only under the condition of not damaging the present main components. In other words, when an excessive heat is applied in the course of manufacturing a foodstuff, the addition is conducted at the unheated final stage, while an excessive heat is not applied in the course of manufacturing foodstuff, the complex material is added together with the raw material before processing.
  • the foodstuffs are not restricted, as far as the form is concerned. For instance, the foodstuffs in liquid form such as beverage or the foodstuffs in solid form such as meat for hamburger can be covered.
  • the present invention relates to a method for reducing the in- blood cholesterol content and suppressing the cholesterol absorption by using the complex or mixed composition of interest in medicinal agents, medicinal injections, foodstuff additives or the like.
  • a method for reducing the in- blood cholesterol content and suppressing the cholesterol absorption by using the complex or mixed composition of interest in medicinal agents, medicinal injections, foodstuff additives or the like includes the cure of high cholesterol symptoms and some of heart diseases.
  • beta-cytosterol 200 mg of beta-cytosterol, a kind of phyto sterol, and 280 mg of catechin, a kind of tannin, were well mixed and dried at normal temperature for 30 minutes.
  • aqueous ethanol solution 50 mg
  • catechin a kind of tannin
  • the solution was heated at 70°C for about 20 minutes.
  • the resulting substance was cooled to the normal temperature over 30 minutes and then acidified by adding 10 ml of fruit vinegar.
  • the acidified solution was further agitated at the normal temperature for 15 minutes and then heated at 70°C for about 5 minutes.
  • the excessive solvent was removed, and the formed product was dried and filtered through a 20 mesh-sieve to produce a uniform product.
  • the complex substance of the present invention reduces the total cholesterol number in the blood as well as the LDL- cholesterol without influencing the absorption of favorable HDL-cholesterol to attain a satisfactory result.
  • the complexes according to the invention are effective in curing high cholesterol symptoms and in preventing heart diseases and hypertension, they can be used not only in medicinal preparations or injections but also can be used in manufacturing health-oriented functional foodstuffs by simply incorporating in other foodstuffs and beverages.

Landscapes

  • Health & Medical Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Medical Informatics (AREA)
  • Botany (AREA)
  • Biotechnology (AREA)
  • Engineering & Computer Science (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention relates to a composition and complex for reducing the cholesterol in the blood, particularly LDL cholesterol, and for curing the cholesteremia or some of heart diseases, as well as to a method for manufacturing those compositions and complex substances, wherein complexes or mixed compositions consisting of phyto-sterols, naturally occurring plant sterols, and tannins, as the main components, are used as pharmaceutical preparations, medicinal injections, food additives or the like to effectuate innovative reduction in the cholesterol value in the blood. Particularly, the complexes and mixed compositions according to the invention have the merit of convenience in that direct addition to the foodstuffs can produce the action of reducing the cholesterol value without doing any harm on human body.

Description

CHOLESTEROL IN BLOOD - LOWERING COMPOSITION AND ITS COMPLEX, AND METHOD FOR PREPARING THEM
FIELD OF THE INVENTION
The present invention relates to the composition and the complex for reducing the cholesterol in the blood, particularly LDL cholesterol, and for curing the cholesteremia or some of heart diseases, as well as to the method for manufacturing those compositions and complex substances, wherein complexes or mixed compositions consisting of phyto-sterols, naturally occurring plant sterols and tannins, as the main components, are used as pharmaceutical preparations, medicinal injections, food additives or the like.
BACKGROUND OF THE INVENTION
The cholesterol is an essential substance in human body, which plays a role in forming cell membrane, steroid hormones or the like. When the in-blood concentration of cholesterol, particularly LDL cholesterol or the lipid is maintained at excessively high level, however, there is a high possibility of heart diseases or arterial sclerosis, which can lead to death or disability.
As one of the methods for reducing the in-blood level of cholesterol, there is a proposed method wherein consumption of foodstuffs rich in the choiesterols or saturated aliphatic acids is suppressed, body weight is cut down and exercise amount is increased. In many cases, however, this method is neither so effective nor so easy to follow. Accordingly, as a more concrete approach, a method for reducing the absorption of cholesterol in intestine tract is proposed, for which method some therapeutic agents and food additives are developed and used. However, this method is associated with some side effects and the efficacy is not so excellent as well.
On the other hand, in relevant studies, it has been repeatedly reported that the plant sterols are effective in controlling the choiesterols in the blood substantially without causing harmful effects (Reference: J. Nutr., 107, 2011 (1977)). Specially, the beta-cytosterol, which is advantageously acquired from bean or rice in easy ways and which turns similar to the cholesterol in structure when the ethyl group at the 24-th carbon is removed, has been confirmed to interfere with the cholesterol absorption in the human body through a competitive reaction (Reference: Atherosclerosis, 28, 325, (1977)).
Naturally occurring plant sterols (phytosterols) have the same skeleton in the structure, only slightly differing in side chains. The plant sterols taken-in together with foodstuffs are mostly either beta-cytosterols or campysterols, some of which are absorbed in the intestine and then discharged outside the body, so that even an over- intake causes no side effect on the human body due to only a minor part of it remaining in the body. Further, beside the plant sterols, their analogous products, i.e. stanol as hydrogenated compounds and their fatty acid ester compounds were also developed as the products for reducing in-blood choiesterols (Reference: J. Lipid Res., 20, 646, (1979); J. Nutr., 107, 1139(1977)), and recently the margarine added with the ester compounds of beta-cytostaneol was reported to reduce the cholesterol level in the blood (Reference: WO/19640). However, in spite of the efficacy of those developed products, the phyto-sterols have, in fact, the drawback that only an extremely limited amount of phyto-sterols is absorbed in micelle of the small intestines. Consequently, difficulty arises that an excessive amount should be taken in order to realize a practical effect. Therefore, there is an urgent need for the development of new products that can reduce the cholesterol level more effectively while overcoming the afore-mentioned drawbacks.
SUMMARY OF THE INVENTION
In order to achieve the above-described object, the complex for reducing the in-blood cholesterol according to the present invention comprises, as the principal components, natural plant sterol ("phyto-sterol") and tannin at the weight ratio of 10: 1 to 1:10.
The present inventors have confirmed that the phyto-sterol/tannin complexes manufactured by mixing naturally occurring plant sterols as harmless safe substances, and tannins have an unexpected synergic effect in reducing the in-blood choiesterols and so completed the present invention based on that finding.
As representative examples of phytosterols, beta-cytosterols, campy-sterols, stigma sterols, fuco-sterols, Brassica sterols may be mentioned. One of those sterols or a mixture of two or more may be used as the principal component for the products according to the invention.
The tannins as described above are generally included in the stems, leaves, roots of plants or the like, and also in the fruits and vegetables including unripe ones, as well as in the seeds of plants. In recent years, it was found that the tannin compounds have various physiological activities, which include, for example, the action of improving the blood circulation, anti-oxidation and other various physiological activations.
The tannins may be classified as (1) catechins and their derivatives, (2) leucoanthocyanins,
(3) anthocyanidins,
(4) chlorogenic acids, which all belong to polyphenolic acids with phenol group(s).
As one component of the complexes according to the invention, the tannin compounds as described above can be used as a single compound or in the form of mixture of two or more compounds.
As the representative example of the catechins, there can be mentioned catechin, which have the carbon skeletons of C6-C3-C6, i.e. a structural characteristic common to the flavonoids, anthocyanins and the like. Under these tannins, catechins
(trans-form), epi-catechin (cis-form), 3-galloyl epi-catechins and 3-galloyl gallocatechins are included.
Typical leucoanthocyanins may include leucoanthocyanidin, luteolinidin and the like.
The anthocyanidins have the basic structure of 3,5,7-trihydroxy flavylium chlorides. The anthocyanidin includes pelargonidin, cyaniding and delphinidin as the representative examples and further includes hirsutidin (7-o-methylmalvidin), aurantinidin (8-hydroxy pelargonidin), apigeninidin (3-deoxy pelargonidin), petunidin
3,5-diglucoside, malvidin 3,5-diglucoside, peonidin 3-menoglucoside, malvin 3- monoglucoside, cyanidin 3-galactoside, cyanidin 7-arabinoside, pelargonidin 3- monoglucoside, pelargonidin 3-galactoside, cyanidin 3-ramnosyl glucoside, cyanidin 3,5-diglucoside, cyanidin 3-diglucoside, cyanidin 3-lutioside and the like.
The representative examples of the above-described polyphenolic acids include chlorogenic acids, caffeine acid, phenyl caffeate, cinnamic acid, gallic acid and the tannic acid that is now known as a complex mixture of various compounds.
As is shown, the tannins have a variety of distributions and contents and they can be relatively easily extracted to give certain desired tannin.
The content ratio between phyto-sterol and tannin as the principal components of the complex according to the invention lies between 10:1 and 1:10 and more preferably between 4:6 and 6:4, each ratio being by weight, as mentioned earlier.
If need be, other known components beside the above principal components may be added to promote the effect of the invention.
The inventors of the present invention have found that the phyto-sterol and tannin even in form of simple mixed composition, not in the form of a complex, has the synergetic effect. Accordingly, the present invention relates to a mixed composition comprising, as the principal components, phyto-sterol and tannin at the weight ratio of 10: 1 to 1 : 10 for reducing the cholesterol in the blood.
However, the complex of phyto-sterol and tannin which is obtained by dissolving the phyto-sterol and tannin together in a solvent and then heat-treating the dissolved mixture at a defined condition further increases the synergic effect of mixing the two ingredients.
Accordingly, the present invention relates to a method for manufacturing a complex of phyto-sterol/tannin as well.
The method for manufacturing the complex for reducing the in-blood cholesterol according to the present invention comprises dissolving the dried phyto- sterol and tannin in a solvent under an acidic condition, subjecting the dissolved mixture to reaction at a temperature from 20 to 100°C, removing the remaining solvent from the product and finally subjecting the crude product to drying.
In particular, the manufacturing method comprises the steps of:
(A) drying phyto-sterol and tannin separately at a normal temperature or near normal temperature; (B) dissolving the dried phyto-sterol and tannin at the weight ratio of
10:1 to 1:10 in a solvent and stirring the dissolved mixture to provide a uniform solution;
(C) heating the resulting solution at a temperature of 60 to 90°C for the period of 3 to 100 minutes and cooling the resulting solution to a normal or near-normal temperature;
(D) acidifying the solution by adding a weak solution, stirring the solution and heating the solution at a temperature of 60 to 90°C for the period of 3 to 100 minutes; and
(E) removing the remaining solvent and drying the produced product.
More preferably, the temperature in the above steps (C) and (D) is about 70°C and the heating period is 5 to 30 minutes. As the solvent used in the step (B), the water, ethanol or a mixture of water and ethanol may be appropriate.
As the weak solution for the step (D), preferably an edible acidic solution and most preferably vinegar from fruit may be used.
The complex and mixed composition according to the invention, as it is, or by adding other necessary ingredients, may be prepared into pharmaceutical formulations, medicinal injections, food additives or the like for reducing the cholesterol level in the blood.
For example, a pharmaceutical formulation may be prepared by adding some vehicle to the above-described complex as the active ingredient. A medicinal injection may be prepared by dissolving the above complex as the active ingredient in distilled water or saline solution as the solvent. Particularly, for the case of food additives that are added to the foodstuffs with high cholesterol content, powder of the complex is simply added to the raw material of foodstuffs and finished foodstuffs.
There is no upper limit to daily dosage of the complex because administering an excessive amount is not particularly harmful for a human body. However, a daily dosage of less than lOg per day for an adult with body weight of 60 kg is particularly preferable.
Therefore, the present invention relates to the agents for reducing cholesterol, injections for reducing cholesterol, food additives for reducing cholesterol, each containing the above-described complexes or mixed compositions as the active ingredients, and various foodstuffs containing the above complexes.
The method for preparing the above agents, injections and foodstuffs is the same as the method for preparing ordinary medicinal agents or injections based on the medicinal active components, and therefore is no more described. For the case of manufacturing foodstuffs containing the present complexes or mixed compositions, addition can be made in a variety of ways only under the condition of not damaging the present main components. In other words, when an excessive heat is applied in the course of manufacturing a foodstuff, the addition is conducted at the unheated final stage, while an excessive heat is not applied in the course of manufacturing foodstuff, the complex material is added together with the raw material before processing. The foodstuffs are not restricted, as far as the form is concerned. For instance, the foodstuffs in liquid form such as beverage or the foodstuffs in solid form such as meat for hamburger can be covered.
Accordingly, the present invention relates to a method for reducing the in- blood cholesterol content and suppressing the cholesterol absorption by using the complex or mixed composition of interest in medicinal agents, medicinal injections, foodstuff additives or the like. Such a method includes the cure of high cholesterol symptoms and some of heart diseases.
While the present invention is described in more detail below along some examples, they are intended only for illustrative purpose and so not to restrict the scope of the invention.
DETAILED DESCRIPTION OF PREFERRED EMBODIMENTS Example 1: Manufacture of the complex of beta-cytosterol and catechin
200 mg of beta-cytosterol, a kind of phyto sterol, and 280 mg of catechin, a kind of tannin, were well mixed and dried at normal temperature for 30 minutes. To the resulting mixture, there was added 50 mg of aqueous ethanol solution, and the mixture was agitated for 1 hour to provide a homogenous solution. The solution was heated at 70°C for about 20 minutes. The resulting substance was cooled to the normal temperature over 30 minutes and then acidified by adding 10 ml of fruit vinegar. The acidified solution was further agitated at the normal temperature for 15 minutes and then heated at 70°C for about 5 minutes. The excessive solvent was removed, and the formed product was dried and filtered through a 20 mesh-sieve to produce a uniform product.
Example 2: Animal test for the complex
30 Sprauque-Dawley rats with the age of 4 weeks were normalized for a week under the laboratory rearing condition and divided into 4 groups. The feed that was added with 1% of cholesterol or 0.5% of cholic acid was supplied to the rats for a week to increase the cholesterol value in the animals' blood. Subsequently, the feed, to which the complex of the invention was added at the concentration of 0.5%, 1% or 3%, was supplied, while the total cholesterol values, LDL-cholesterol values and HDL- cholesterol values were measured over the time period. The results are listed in Table 1.
Figure imgf000010_0001
Figure imgf000011_0001
(The listed data represent the result after 2 weeks for the groups 2 and 3, and the result after 5 days for the group 4).
As can be seen from the above table 1, the effect of reducing the cholesterol in the blood, exhibited by the complex according to the invention, was very excellent. It is also understood that at the low concentration of the complex in Groups 2 and 3, the effect showed up so slowly that the total cholesterol values were reduced 18% and 27% respectively after two weeks, while at the higher complex concentration of 3% in Group 4, reduction of 34% in the cholesterol value was achieved only in 5 days.
Accordingly, it is confirmed that the complex substance of the present invention reduces the total cholesterol number in the blood as well as the LDL- cholesterol without influencing the absorption of favorable HDL-cholesterol to attain a satisfactory result.
Industrial Applicability
As described above, as the complexes according to the invention are effective in curing high cholesterol symptoms and in preventing heart diseases and hypertension, they can be used not only in medicinal preparations or injections but also can be used in manufacturing health-oriented functional foodstuffs by simply incorporating in other foodstuffs and beverages.

Claims

WHAT IS CLAIMED IS:
1. Complex for reducing the cholesterol in the blood, characterized in comprising, as the principal components, natural plant sterol ("phyto-sterol") and tannin at the weight ratio of 10:1 to 1:10.
2. The complex for reducing the cholesterol in the blood according to Claim 1, in which said phyto sterol is one or a mixture of two or more selected from beta- cytosterols, campy-sterols, stigma sterols, fuco-sterols and Brassica sterols;
Said tannin is one or a mixture of two or more selected from compounds belonging to the below:
(1) catechins and their derivatives,
(2) leucoanthocyanins, (3) anthocyanidins,
(4) chlorogenic acids, which all belong to polyphenolic acids with phenol group(s).
3. The complex for reducing the cholesterol in the blood according to Claim 2, in which
as said catechins and their derivatives, there are catechins (trans-form), epi- catechin (cis-form), 3-galloyl epi-catechins, 3-galloyl gallocatechins and the like; ' as said leucoanthocyanins, there are leucoanthocyanidin, luteolinidin and the like; as said anthocyanidins, there are anthocyanidin, pelargonidin, cyanidin, delphinidin, hirsutidin (7-o-methylmalvidin), aurantinidin (8-hydroxy pelargonidin), apigeninidin (3-deoxy pelargonidin), petunidin 3,5-diglucoside, malvidin 3,5- diglucoside, peonidin 3-menoglucoside, malvin 3 -monoglucoside, cyanidin 3- galactoside, cyanidin 7-arabinoside, pelargonidin 3 -monoglucoside, pelargonidin 3- galactoside, cyanidin 3-ramnosyl glucoside, cyanidin 3,5-diglucoside, cyanidin 3- diglucoside, cyanidin 3-lutioside and the like; as said polyphenolic acids, there are chlorogenic acids, caffeine acid, phenyl caffeate, cinnamic acid, gallic acid, the tannic acid and the like.
4. Composition for reducing the cholesterol in the blood, characterized in comprising, as the principal components, natural plant sterol ("phyto-sterol") and tannin at the weight ratio of 10:1 to 1:10.
5. Medicinal agents, medicinal injections or food additives containing, as the active ingredients, the composites or the compositions for reducing the cholesterol in the blood according to one of Claims 1 to 4.
6. Foodstuffs containing, as the active ingredients, the composites or the compositions for reducing the cholesterol in the blood according to one of Claims 1 to 4.
7. Method for manufacturing the phyto-sterόl and tannin complex for reducing the in-blood cholesterol, characterized in comprising dissolving the dried phyto-sterol and tannin in a solvent under an acidic condition, subjecting the dissolved mixture to reaction at a temperature from 20 to 100°C, removing the remaining solvent from the product and finally subjecting the crude product to drying.
8. Method for manufacturing the phyto-sterol and tannin complex for reducing the in-blood cholesterol according to Claim 7, in which the manufacturing method comprises the steps of:
(A) drying phyto-sterol and tannin separately at a normal temperature or near normal temperature; (B) dissolving the dried phyto-sterol and tannin at the weight ratio of 10:1 to
1:10 in a solvent and stirring the dissolved mixture to provide a uniform solution;
(C) heating the resulting solution at a temperature of 60 to 90°C for the period of 3 to 100 minutes and cooling the resulting solution to a normal or near- normal temperature;
(D) acidifying the solution by adding a weak solution, stirring the solution and heating the solution at a temperature of 60 to 90°C for the period of 3 to 100 minutes; and
(E) removing the remaining solvent and drying the produced product.
9. Method for manufacturing the phyto-sterol and tannin complex for reducing the in-blood cholesterol according to Claim 8, in which the temperature in the above steps (C) and (D) is about 70°C and the heating period is 5 to 30 minutes; the solvent used in the step (B) is water, ethanol, or a mixture of water and ethanol; and the weak acidic solution used in the step (D) is vinegar from fruit.
PCT/KR2000/001034 2000-09-25 2000-09-25 Cholesterol in blood-lowering composition and its complex, and method for preparing them Ceased WO2002024212A1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
PCT/KR2000/001034 WO2002024212A1 (en) 2000-09-25 2000-09-25 Cholesterol in blood-lowering composition and its complex, and method for preparing them
AU2000274550A AU2000274550A1 (en) 2000-09-25 2000-09-25 Cholesterol in blood-lowering composition and its complex, and method for preparing them

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/KR2000/001034 WO2002024212A1 (en) 2000-09-25 2000-09-25 Cholesterol in blood-lowering composition and its complex, and method for preparing them

Publications (1)

Publication Number Publication Date
WO2002024212A1 true WO2002024212A1 (en) 2002-03-28

Family

ID=19198267

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2000/001034 Ceased WO2002024212A1 (en) 2000-09-25 2000-09-25 Cholesterol in blood-lowering composition and its complex, and method for preparing them

Country Status (2)

Country Link
AU (1) AU2000274550A1 (en)
WO (1) WO2002024212A1 (en)

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1264596A3 (en) * 2001-06-05 2003-01-08 Kao Corporation Use of a ferulic acid derivative as a preventive or remedy for hypertension
WO2007063158A2 (en) 2005-11-30 2007-06-07 La Morella Nuts, S.A. Functional food having positive effects in the prevention of cardiovascular diseases
US7772195B2 (en) * 2004-07-29 2010-08-10 Board Of Trustees Of Michigan State University Methods and compositions for the treatment of obesity, insulin related diseases and hypercholesterolemia
US7811781B2 (en) 2005-07-06 2010-10-12 Btg International Limited Core 2 β(1,6)-acetylglycosaminyltransferase as diagnostic marker for atherosclerosis
US7906493B2 (en) 2003-12-22 2011-03-15 Btg International Limited Core 2 GlcNAc-T inhibitors
US7998943B2 (en) 2005-07-06 2011-08-16 Btg International Limited Core 2 GlcNAc-T inhibitors III
US8197794B2 (en) 2003-12-22 2012-06-12 Ms Therapeutics Limited Core 2 GlcNAc-T inhibitors
US8609633B2 (en) 2005-07-06 2013-12-17 Ms Therapeutics Limited Core 2 GlcNAc-T inhibitors

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20000019718A (en) * 1998-09-15 2000-04-15 박호군 Composition comprising tannin or phenol-type compounds derived from tannin for preventing and treating hyperlipidemia, arteriosclerosis and liver disease

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20000019718A (en) * 1998-09-15 2000-04-15 박호군 Composition comprising tannin or phenol-type compounds derived from tannin for preventing and treating hyperlipidemia, arteriosclerosis and liver disease

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
AGRIC. BIOL. CHEM., vol. 54, no. 1, 1990, pages 171 - 175 *
AM. J. MED., vol. 107, no. 6, 1999, pages 588 - 594 *
LIPIDS, vol. 27, no. 3, 1992, pages 181 - 186 *
PHARMACOL. RES., vol. 35, no. 6, 1997, pages 505 - 512 *

Cited By (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1264596A3 (en) * 2001-06-05 2003-01-08 Kao Corporation Use of a ferulic acid derivative as a preventive or remedy for hypertension
US6894077B2 (en) 2001-06-05 2005-05-17 Kao Corporation Preventive or remedy for hypertension
US7534815B2 (en) 2001-06-05 2009-05-19 Kao Corporation Preventive or remedy for hypertension
US7939563B2 (en) 2001-06-05 2011-05-10 Kao Corporation Remedy for hypertension
US7906493B2 (en) 2003-12-22 2011-03-15 Btg International Limited Core 2 GlcNAc-T inhibitors
US8197794B2 (en) 2003-12-22 2012-06-12 Ms Therapeutics Limited Core 2 GlcNAc-T inhibitors
US7772195B2 (en) * 2004-07-29 2010-08-10 Board Of Trustees Of Michigan State University Methods and compositions for the treatment of obesity, insulin related diseases and hypercholesterolemia
US8198249B2 (en) * 2004-07-29 2012-06-12 Board Of Trustees Of Michigan State University Methods and compositions for the treatment of obesity, insulin related diseases and hypercholesterolemia
US7811781B2 (en) 2005-07-06 2010-10-12 Btg International Limited Core 2 β(1,6)-acetylglycosaminyltransferase as diagnostic marker for atherosclerosis
US7998943B2 (en) 2005-07-06 2011-08-16 Btg International Limited Core 2 GlcNAc-T inhibitors III
US8609633B2 (en) 2005-07-06 2013-12-17 Ms Therapeutics Limited Core 2 GlcNAc-T inhibitors
WO2007063158A2 (en) 2005-11-30 2007-06-07 La Morella Nuts, S.A. Functional food having positive effects in the prevention of cardiovascular diseases

Also Published As

Publication number Publication date
AU2000274550A1 (en) 2002-04-02

Similar Documents

Publication Publication Date Title
Igile et al. Nutritional assessment of Vernonia amygdalina leaves in growing mice
EP0282002A2 (en) Compositions of oats and nettle extracts to be used as a food additive or pharmaceutical preparation in human health care
JP2007535576A (en) Nutritional composition that promotes rapid weight loss, burns calories, increases heat generation, assists in energy metabolism and / or suppresses appetite
US20150201661A1 (en) Bamboo extracts, compositions and uses thereof
AU2007245223C1 (en) Fat absorption inhibitor
Elhassaneen et al. Effect of some plant parts powder on obesity complications of obese rats
WO2011112118A1 (en) Premix for food for farm animals
CN106173194A (en) A kind of biological antioxidant of animal feed
WO2002024212A1 (en) Cholesterol in blood-lowering composition and its complex, and method for preparing them
KR20100109697A (en) Functional composition with the effects of improving hyperlipidemia and reducing body weight
RU2115336C1 (en) Bioactive preparation "propolin"
JPH1175770A (en) Lipid peroxide production inhibitor, its production method and use
CN109645232A (en) A kind of Chinese herbal medicine composite feed additive for treating animal diarrhea
KR101045279B1 (en) Composition of functional food having anti-obesity effect
CN120114523A (en) A lipase inhibitor with specific structure and its preparation method and application
KR101793098B1 (en) Natural plant mixed extracts that regulate heat of the skin and a cosmetic composition for skin heat anti-aging that containing the same
RU2375434C2 (en) Composition of balsam components
KR100466946B1 (en) Feed for Duck and Method of Feeding Duck with the Feed
JP6778506B2 (en) Functional food composition
CN106173195A (en) A kind of animal feed preparation method of biological antioxidant
JPH07112979B2 (en) Active oxygen free radical scavenger
JP2009221158A (en) Neutral fat reducing agent and body fat increase inhibitor
El-Maaty et al. Performance of hybrid chickens as influenced by phytogenic extracted meal-supplemented diet as antibiotic alternatives during summer
RU2392825C1 (en) Feed supplement for farm livestock
JP2009196967A (en) Agent for increasing relative quantity of polyunsaturated fatty acid in blood, and pharmaceutical composition, quasi-drug, cosmetics, edible composition and animal feed containing the agent

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 1020037004223

Country of ref document: KR

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

32PN Ep: public notification in the ep bulletin as address of the adressee cannot be established

Free format text: NOTING THE LOSS OF RIGHTS PURSUANT TO RULE 69 (1)EPC (EPO COMMUNICATION FORM 1205A DATED 30.07.2003)

122 Ep: pct application non-entry in european phase
WWR Wipo information: refused in national office

Ref document number: 1020037004223

Country of ref document: KR

WWW Wipo information: withdrawn in national office

Ref document number: 1020037004223

Country of ref document: KR

NENP Non-entry into the national phase

Ref country code: JP